bèta
Trial Radar AI
De klinische studie NCT06196008 voor Longcarcinoom is recruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag.
Eén studie komt overeen met de filtercriteria
Kaartweergave

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Recruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT06196008 is een interventioneel studie bij Longcarcinoom met de status recruterend. Het doel is om 382 deelnemers te includeren vanaf 5 december 2023. De studie wordt geleid door City of Hope Medisch Centrum en de voltooiing is gepland op 16 mei 2028. Laatste update op ClinicalTrials.gov: 16 september 2025.
Beknopte samenvatting
This clinical trial compares telephone-based physical activity coaching to self monitored physical activity for improving physical function in older adults who are undergoing surgery for lung cancer and their caregivers. Lung cancer surgery in older adults is associated with functional declines and unique challenges. Performing physical activity around the time of surgery has been shown to improve functional outcomes in patients and exercise programs delivered via telehealth may improve access and convenience for patients and minimize participant burden. Telephone-based physical activity coaching may improve physical functioning for older adults with lung cancer who are undergoing surgery.
Uitgebreide beschrijving
PRIMARY OBJECTIVE:

I. To compare changes from baseline in objective patient functional capacity as measured by 6 minute walk test (6MWT) at day 30 post-discharge between the two comparators.

SECONDARY OBJECTIVES:

I. To compare the following outcomes between the two comparators:

Ia. 6MWT at 60 and 180 days post discharge; Ib. Short Physical Performance Battery (SPPB) at 30, 60, and 180 days post-discharge; Ic. The following scores at 30, 60, and 180 days post-discharge: a) patient and family caregiver (FCG) reported self-efficacy; b) patient and FCG reported physical function; c) and patient and FCG quality of life (QOL); Id. Patient time at home and away from the hospital through 60 days post-discharge; Ie. Hospital readmissions rate and postoperative complications through 60 days post-discharge.

EXPLORATORY OBJECTIVES:

I. To explore associations between comparators, outcomes, and the following:

Ia. Perioperative, image-based sarcopenia using standard-of care preoperative chest computed tomography (CT) scans; Ib. Pedometer documented daily steps; Ic. Participant demographic and clinical characteristics.

OUTLINE: Patients and their FCG are randomized together to 1 of 2 arms.

ARM I: Patients attend telephone-based coaching sessions over 20-50 minutes once 7-14 days before standard of care surgery, and then at days 7, 14, 21, and 51 post-discharge, for a total of 5 sessions. Patients also receive a personalized physical activity program and set fitness goals. FCGs also receive coaching and serve as a walking buddy for their patient. Patients and FCGs also wear an activity monitor throughout the trial.

ARM II: Patients receive written educational materials on physical activity and cancer survivorship. Patients and FCGs also wear an activity monitor throughout the trial.

After completion of study intervention, patients are followed up at days 60 and 180 post-discharge.

Officiële titel

SR2204: A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults With Lung Cancer and Their Family Caregivers

Aandoeningen
Longcarcinoom
Publicaties
Wetenschappelijke artikelen en onderzoekspapers gepubliceerd over deze klinische studie:
Andere studie-ID's
NCT-ID
Startdatum (Werkelijk)
2023-12-05
Laatste update geplaatst
2025-09-16
Verwachte einddatum
2028-05-16
Inschrijving (Geschat)
382
Studietype
Interventioneel
FASE
N.v.t.
Status
Recruterend
Primaire doel
Ondersteunende zorg
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Geen (Open-label)
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
ExperimenteelArm I (Telephone-based coaching session)
Patients attend telephone-based coaching sessions over 20-50 minutes once 7-14 days before standard of care surgery, and then at days 7, 14, 21, and 51 post-discharge, for a total of 5 sessions. Patients also receive a personalized physical activity program and set fitness goals. FCGs also receive coaching and serve as a walking buddy for their patient. Patients and FCGs also wear an activity monitor throughout the trial.
Onderwijsinterventie
Attend telephone-based coaching sessions
Oefeninterventie
Receive a personalized physical activity program, set fitness goals
Gebruik en evaluatie van medisch apparaat
Wear activity monitor
Testen van fysieke prestaties
Ancillary studies
Beoordeling van de kwaliteit van leven
Ancillary studies
Vragenlijstadministratie
Ancillary studies
Actieve comparatorArm II (Written education)
Patients receive written educational materials on physical activity and cancer survivorship. Patients and FCGs also wear an activity monitor throughout the trial.
Onderwijsinterventie
Receive written educational materials on physical activity and standard preoperative care
Gebruik en evaluatie van medisch apparaat
Wear activity monitor
Testen van fysieke prestaties
Ancillary studies
Beoordeling van de kwaliteit van leven
Ancillary studies
Vragenlijstadministratie
Ancillary studies
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Objective patient functional capacity
Measured by the 6 minute walk test (6MWT). Analysis will be a study group comparison via linear regression model.
At 30 days post discharge
Secundaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Functional capacity
Measured by 6MWT. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 60 and 180 days post discharge
Lower extremity function
Measured by the short physical performance battery. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 30, 60 and 180 days post discharge
Patient and caregiver reported self efficacy
Measured by patient reported outcomes measurement information system (PROMIS) self efficacy. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 30, 60, and 180 days post discharge
Patient and caregiver reported physical function
Measured by PROMIS physical function. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 30, 60 and 180 days post discharge
Patient reported quality of life
Measured by Functional Assessment of Cancer Therapy -Lung for patients. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 30, 60 and 180 days post discharge
Caregiver reported quality of life
Measured by City of Hope-Quality of Life-Family Caregiver for caregivers. Will be assessed via repeated measures linear regression model with adjustment for baseline value of the outcome, stratification factors, and time point.
At 30, 60 and 180 days post discharge
Patient time at home and away from the hospital
Will be compared by study arm by linear regression models.
Up to 60 days post discharge
Hospital readmissions
Will be compared by study arm via logistic regression.
Up to 60 days post discharge
Postoperative complications
Will be compared by study arm via logistic regression.
Up to 60 days post discharge
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
Accepteert gezonde vrijwilligers
Ja
  • PATIENT: Documented informed consent of the participant and/or legally authorized representative

  • PATIENT: Agreement to allow the use of preoperative chest CT scan for exploratory analysis, if available

  • PATIENT: Agreement to wear pedometer during study duration

    • If unwilling, exceptions may be granted with study primary investigator (PI) approval
  • PATIENT: Age >= 65 years

  • PATIENT: Ability to read and understand English or Spanish and willingness to complete participant-reported outcomes and assessments

  • PATIENT: Diagnosis of lung cancer or presumed lung cancer (as determined by surgeons) in patient

  • PATIENT: Scheduled to undergo lung surgery for lung cancer or suspected lung cancer with curative intent (neoadjuvant therapy allowed)

  • PATIENT: Adults lacking capacity to consent in the opinion of the attending surgeon will not be enrolled

  • FCG: Documented informed consent of the participant and/or legally authorized representative

  • FCG: Age >= 18

  • FCG: Ability to read and understand English or Spanish and willingness to complete participant-reported outcomes and assessments

  • FCG: Adults lacking capacity to consent in the opinion of the attending surgeon will not be enrolled

  • PATIENT: Lung surgery is scheduled in less than 14 calendar days from the time of registration
  • PATIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including exercise program and compliance issues related to feasibility/logistics)
  • FCG: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including exercise program and compliance issues related to feasibility/logistics)
Centraal Contactpersoon
Contact: Dan Raz, MD, 626-471-7100, [email protected]
13 Studielocaties in 1 landen

California

University of California, Davis, California, 95616, United States
Lisa Brown, MD, Contact, 916-734-3861, [email protected]
Lisa Brown, MD, Hoofdonderzoeker
Nog niet rekruterend
City of Hope Medical Center, Duarte, California, 91010, United States
Dan Raz, Contact, 626-471-7100, [email protected]
Dan Raz, Hoofdonderzoeker
Recruterend
Standard University, Stanford, California, 94305, United States
Natalie Lui, MD, Contact, 415-378-1406, [email protected]
Natalie Lui, MD, Hoofdonderzoeker
Recruterend
Standford University, Stanford, California, 94305, United States
Natalie Lui, MD, Contact, 415-378-1406, natalielui@[email protected]
Natalie Lui, MD, Hoofdonderzoeker
Nog niet rekruterend

Connecticut

Yale New Haven Medical Center, New Haven, Connecticut, 06510, United States
Justin Blasberg, MD, Contact, 646-251-2670, [email protected]
Justin Blasberg, MD, Hoofdonderzoeker
Recruterend

Florida

Moffitt Cancer Center, Tampa, Florida, 33612, United States
Eric Toloza, MD, PhD, Contact, 813-745-7282, [email protected]
Eric Toloza, MD, PhD, Hoofdonderzoeker
Recruterend

Illinois

Northwestern University, Evanston, Illinois, 60208, United States
Samuel Kim, MD, Contact, 312-694-6469, [email protected]
Samuel Kim, MD, Hoofdonderzoeker
Nog niet rekruterend

Massachusetts

Massachusetts General Hospital (MGH) / Harvard, Boston, Massachusetts, 02114, United States
Chi-Fu J. Yang, MD, Contact, 617-726-6826, [email protected]
Chi-Fu J. Yang, MD, Hoofdonderzoeker
Recruterend

Mississippi

University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States
Jacob Moremen, MD, Contact, 601-984-5170, [email protected]
Jacob Moremen, MD, Hoofdonderzoeker
Recruterend

North Carolina

Duke University, Durham, North Carolina, 27710, United States
Betty Tong, MD, Contact, 919-613-4690, [email protected]
Betty Tong, MD, Hoofdonderzoeker
Recruterend

Ohio

Ohio State University, Columbus, Ohio, 43210, United States
Peter Kneuertz, MD, Contact, 614-293-9059, [email protected]
Peter Kneuertz, MD, Hoofdonderzoeker
Nog niet rekruterend

Tennessee

University of Tennessee Health Science Center, Memphis, Tennessee, 38120, United States
Thomas Ng, MD, Contact, 901-226-0458, [email protected]
Thomas Ng, MD, Hoofdonderzoeker
Recruterend

Texas

MD Anderson Cancer Center, Houston, Texas, 77030, United States
Mara Antonoff, MD, Contact, 612-964-6469, [email protected]
Mara Antonoff, MD, Hoofdonderzoeker
Recruterend